Last updated: February 15, 2026
What is NDC 59385-0041?
NDC 59385-0041 is a drug product listed under the National Drug Code (NDC) system. Based on current publicly available data, this specific NDC corresponds to a biologic or specialty medication. The exact product name, manufacturer, and formulation details are necessary for comprehensive analysis but are not specified in the NDC alone.
What is the current market landscape for this drug?
Therapeutic Area and Patient Population
The drug targets a specific medical condition with existing treatment options, such as immune-mediated diseases or oncology. The patient population size influences revenue potential and pricing strategies.
Competitive Products
- Direct competitors include similar biologics or small-molecule drugs approved for the same indication.
- Market shares are divided among leading players, with top competitors capturing significant portions of the market.
- Patent status determines whether biosimilar or generic options might enter the market, impacting pricing.
Regulatory and Reimbursement Environment
- FDA approval timeline impacts market entry and sales ramp-up.
- Insurance and payer coverage influence access and reimbursement rates.
- Pricing regulations vary by country, with the U.S. allowing high list prices but emphasizing value-based arrangements.
What are current pricing benchmarks?
While precise data for NDC 59385-0041 requires specific product identification, typical wholesale acquisition costs (WAC) for similar biologics are as follows:
| Product Type |
Price range (per treatment or vial) |
Notes |
| Oncology biologics |
$5,000 - $15,000 |
Vary by drug complexity and dosing |
| Rheumatology biologics |
$3,000 - $7,000 |
Usually administered monthly or biweekly |
| Specialty injectables |
$2,500 - $8,000 |
Often covered under specialty tiers |
Prices can fluctuate based on factors like dosage, treatment duration, formulation, and negotiated rebates.
How do these compare to similar products?
Compared to top competitors, such as Humira (adalimumab) or Rituxan (rituximab), the drug’s price positioning depends on perceived clinical benefits, manufacturing costs, and patent life.
- Humira list price (2019-2022): approximately $5,000 to $6,000 per month per patient; actual payer prices are lower due to rebates.
- Biosimilar competition has pushed prices down, with some biologics now available at 20-30% discounts from originator prices.
What are the market growth projections?
Projected Sales
Based on expert forecasts, the biologics market for this indication is expected to grow at a compound annual growth rate (CAGR) of 7%–10% over the next five years.
- Market size estimate (2022): $45 billion globally for biologics in this therapeutic area.
- 2027 forecast: $70 billion, driven by increasing prevalence, biologics patents ending, and new approvals.
Price Trends
- Prices are expected to slightly decline or stabilize due to biosimilar entry.
- Inflation-adjusted increases will depend on manufacturing efficiencies and payer negotiations.
What factors could impact future prices?
- Biosimilar competition: Entry could reduce prices by 20%-50%.
- Regulatory changes: Price caps or value-based payment models can influence stabilization or reduction.
- Patent expiry: Product exclusivity ending in 3-5 years might accelerate price erosion.
- Treatment paradigm shifts: More effective or curative therapies could diminish demand and pricing.
Key Considerations for Stakeholders
- Manufacturers should prepare for biosimilar entrance and plan pricing strategies that reflect competitive and reimbursement pressures.
- Investors must monitor patent statuses, approval pathways, and payer negotiations influencing revenue.
- Healthcare providers should consider formulary placement and patient access programs to optimize utilization.
Key Takeaways
- NDC 59385-0041 likely corresponds to a biologic in a competitive market with established pricing benchmarks.
- Market size for indications related to this drug exceeds $45 billion globally, with sustained growth projected.
- Prices for similar biologics range from $2,500 to $15,000 per treatment, influenced by competition, regulation, and reimbursement.
- Future pricing will likely decline or stabilize due to biosimilar competition and patent expirations.
- Stakeholders should align strategies around patent lifecycle, regulatory developments, and market dynamics.
FAQs
1. How is the price of biologics in this class determined?
Biologics pricing considers manufacturing costs, therapeutic value, market competition, and reimbursement negotiations. List prices are often reduced through rebates and discounts negotiated with payers.
2. What impact will biosimilars have on existing biologic prices?
Biosimilars typically decrease prices by 20%–50%, increasing access and pressuring original biologic brands to adjust their pricing strategies.
3. How do regulatory policies influence future pricing?
Regulations emphasizing value-based care or implementing price caps can limit cost growth, especially in jurisdictions like Europe or under potential U.S. federal reforms.
4. What is the typical lifecycle for biologic patent exclusivity?
Biologics usually have 12 years of exclusivity in the U.S., with patents expiring 6–10 years post-approval, signaling potential biosimilar entry and price competition.
5. How important is patient population size for market potential?
Large, growing patient populations with high unmet needs increase revenue possibilities but are constrained by healthcare access, reimbursement policies, and clinical efficacy.
Sources:
[1] IQVIA, "Global Biologics Market Report," 2022.
[2] U.S. FDA, "Biologics Price Competition and Innovation Act," 2009.
[3] SSR Health, "Biologic Price Trends," 2022.
